Evidence map›Paper›PMID 37207153›Full record

ArticleFrontiers in oncology2023

WIPI2 enhances the vulnerability of colorectal cancer cells to erastin via bioinformatics analysis and experimental verification.

Liying Yu, Yan Luo, Xile Ding, Miaomiao Tang, Huan Gao, Renfang Zhang, Mingfu Chen, Yuchen Liu, Qiongxia Chen, Yanli Ouyang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Targeting ferroptosis to overcome drug resistance in gastrointestinal cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Liying YuDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Yan LuoDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Xile DingDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Miaomiao TangDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Huan GaoDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Renfang ZhangDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Mingfu ChenDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Yuchen LiuCancer Institute, School of Medicine, Jianghan University, Wuhan, China.
Qiongxia ChenDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Yanli OuyangDepartment of Pathology, Fifth Hospital in Wuhan, Wuhan, China.
Xiang WangDepartment of Histology and Embryology, School of Medicine, Jianghan University, Wuhan, China.
Hongyan ZhenDepartment of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China.
Jianghan University · CNFifth Hospital In Wuhan · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: WD Repeat Domain Phosphoinositide Interacting 2 (WIPI2) is a WD repeat protein that interacts with phosphatidylinositol and regulates multiprotein complexes by providing a b-propeller platform for synchronous and reversible protein-protein interactions assembled proteins. Ferroptosis is a novel iron-dependent form of cell death. It is usually accompanied with the accumulation of membrane lipid peroxides. Our study is to focus on investigating the effect of WIPI2 on the growth and ferroptosis of colorectal cancer (CRC) cells and its potential mechanism. Methods: We analyzed the expression of WIPI2 in colorectal cancer versus normal tissues through The Cancer Genome Atlas (TCGA), and the relationship between clinical traits and WIPI2 expression and prognosis was assessed by univariate and multifactorial cox analysis. Next, we constructed the siRNAs targeting the WIPI2 sequence si-WIPI2 to further investigate the mechanism of WIPI2 in CRC cells through vitro experiments. Results: Public data from the TCGA platform showed that WIPI2 expression was significantly elevated in colorectal cancer tissues compared to paracancerous tissues, and high WIPI2 expressionpredicted poor prognosis for CRC patients. Moreover, we found that the knockdown of WIPI2 expression could inhibit the growth and proliferation of HCT116 and HT29 cells. Furthermore, we found that the expression level of ACSL4 decreased and that of GPX4 increased when WIPI2 was knocked down, suggesting that WIPI2 can potentially positively regulate CRC ferroptosis. Meanwhile, both NC and si groups were able to further inhibit cell growth activity, as well as increase WIPI2 and decrease GPX4 expression when treated with Erastin, but the rate of cell viability inhibition and the trend of protein changes were more significantly in the NC group than si groups, which indicated that Erastin induced CRC ferroptosis through the WIPI2/GPX4 pathway thereby enhancing the sensitivity of colorectal cancer cells to Erastin. Conclusions: Our study suggested that WIPI2 had a promotional effect on the growth of colorectal cancer cells, and it also played an important role in the ferroptosis pathway.

Indexed as

colorectal cancererastinferroptosisglutathione peroxidase 4WIPI2

Identifiers

PMID37207153
PMCPMC10189881
OpenAlexW4368376879

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.